Wisconsin Pharmacal Company, LLC v. Nebraska Cultures of California, Inc.

2016 WI 14, 367 Wis. 2d 221
CourtWisconsin Supreme Court
DecidedMarch 1, 2016
Docket2013AP000687
StatusPublished
Cited by27 cases

This text of 2016 WI 14 (Wisconsin Pharmacal Company, LLC v. Nebraska Cultures of California, Inc.) is published on Counsel Stack Legal Research, covering Wisconsin Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wisconsin Pharmacal Company, LLC v. Nebraska Cultures of California, Inc., 2016 WI 14, 367 Wis. 2d 221 (Wis. 2016).

Opinions

PATIENCE DRAKE ROGGENSACK, C.J.

¶ 1. We review a published decision of the court of appeals1 reversing an order of the Ozaukee County Circuit Court2 that granted summary judgment to The Netherlands Insurance Company (Netherlands) and Evan-ston Insurance Company (Evanston). Our review centers on a coverage dispute between the insurers and their respective insureds, Jeneil Biotech, Inc. (Jeneil) and Nebraska Cultures of California, Inc. (Nebraska Cultures). The underlying claims against the insureds arise from their supplying a defective ingredient for incorporation into the plaintiffs, Wisconsin Pharmacal Company (Pharmacal), probiotic supplement tablets.

f 2. The insurers argue that the insurance policies do not provide coverage for damages that may arise out of the underlying claims against the insureds. Specifically, the issues before us are: (1) whether the incorporation of a defective ingredient into the supplement tablets constitutes "property damage" caused by an "occurrence" under the policies' language; and (2) if there is "property damage" caused by an "occurrence," whether any of the policies' exclusions apply to negate coverage.

¶ 3. We conclude that there is no "property damage" caused by an "occurrence" because the incorporation of a defective ingredient into the supplement [231]*231tablets did not damage other property and did not result in loss of use of property. We further conclude that, even if the incorporation of a defective ingredient were to constitute "property damage" caused by an "occurrence," certain exclusions in both policies apply to negate coverage. Accordingly, we reverse the decision of the court of appeals.

I. BACKGROUND

¶ 4. Pharmacal supplies a Daily Probiotic Feminine Supplement to a major retailer. This supplement is in the form of a chewable tablet and contains various ingredients, including a probiotic bacterial species known as Lactobacillus rhamnosus (LRA). In July of 2008, Pharmacal contacted Nutritional Manufacturing Services, LLC to manufacture supplement tablets containing LRA. Nutritional Manufacturing agreed to procure LRA and manufacture supplement tablets containing that ingredient. In order to procure LRA for production of supplement tablets, Nutritional Manufacturing contacted Nebraska Cultures, which agreed to supply LRA. Nebraska Cultures then contracted with Jeneil to supply LRA to Nebraska Cultures for subsequent sale to Nutritional Manufacturing. Nutritional Manufacturing thereafter obtained the ingredient from Nebraska Cultures along with a "Certificate of Analysis," representing the ingredient as LRA.

f 5. Having supposedly acquired LRA from Nebraska Cultures, Nutritional Manufacturing manufactured supplement tablets using the provided ingredient, which was defective because it constituted a different species of bacteria, Lactobacillus acidophilus (LA), rather than LRA. This manufacturing process required blending other ingredients that were obtained from other vendors, with the defective probiotic [232]*232ingredient supplied by Nebraska Cultures and Jeneil. Once all of the ingredients were blended together, they were compressed into tablet form. Once mixed and compressed into tablet form, none of the ingredients could be separated from one another. After manufacturing supplement tablets, Nutritional Manufacturing supplied them to Pharmacal, which, in turn, packaged and shipped them to the retailer.

¶ 6. In April of 2009, the retailer notified Phar-macal that the supplement did not contain LRA but, rather, it contained LA. Pharmacal performed independent testing on supplement tablets and confirmed that they contained LA rather than the contracted-for LRA. Upon this confirmation, Pharmacal notified the retailer that the supplements were mislabeled as containing LRA when they actually contained LA. In May of 2009, the retailer recalled the supplement. After the recall, Pharmacal destroyed the supplement tablets containing the defective ingredient.

f 7. Nutritional Manufacturing assigned any and all of its causes of action against Nebraska Cultures and Jeneil to Pharmacal. On January 14, 2011, Pharmacal filed suit against Nebraska Cultures and its general liability insurer, Evanston, as well as Jeneil and its general liability insurer, Netherlands. Pharmacal alleged numerous causes of action,3 including various tort and contract claims. Additionally, Nebraska Cultures filed a cross claim against Jeneil for negligence. In October of 2011, the circuit court dismissed with prejudice all of Pharmacal's claims against Jeneil and Netherlands. With respect to the claims against Nebraska Cultures and Evanston, the circuit court [233]*233dismissed with prejudice all tort claims. Therefore, the remaining claims include: (1) Nebraska Cultures' cross claim against Jeneil for negligence;4 and (2) Pharmacal's various contract-based claims against Nebraska Cultures. All of these claims allege that Jeneil and Nebraska Cultures incorrectly supplied LA to Nutritional Manufacturing and Pharmacal when the parties had contracted for LRA.

f 8. Subsequently, Netherlands and Evanston moved to bifurcate and stay the merits of the proceedings pending the circuit court's determination of whether their respective insurance policies provided coverage, thereby triggering the insurers' duties to defend and indemnify. Netherlands and Evanston moved for summary judgment, arguing that the insurance policies did not cover any damages that may arise out of the remaining causes of action against Jeneil and Nebraska Cultures because there was no property damage caused by an occurrence.

¶ 9. In October of 2012 and January of 2013, the circuit court held two hearings5 on the coverage issue and ultimately granted the insurers' motions for summary judgment. The circuit court concluded that the facts of the case did not trigger the insurers' duties to defend. Specifically, the circuit court concluded that the incorporation of a defective probiotic ingredient into the tablets did not constitute property damage [234]*234caused by an occurrence because it harmed only the product itself, which is an integrated system.

¶ 10. The court of appeals reversed the circuit court's grant of summary judgment, concluding that the policies provided coverage. Wis. Pharmacal Co. v. Neb. Cultures of Cal., Inc., 2014 WI App 111, 358 Wis. 2d 673, 856 N.W.2d 505. The court of appeals concluded that the integrated system rule was not relevant to the coverage dispute and that the incorporation of a defective ingredient constituted property damage to the product (the probiotic supplement tablets) caused by an occurrence under the policies' language and that no exclusion negated coverage. Id,., ff 20-26. The court of appeals also held that Netherlands breached its duty to defend6 by "reject[ing] Jeneil's initial tender, prior to the discovery of additional facts bearing on coverage." Id., ¶ 39.

¶ 11. We granted the insurers' joint petition for review.

II. DISCUSSION

A. Standard of Review

f 12. Reviewing a grant of summary judgment, we independently apply the same methodology as the circuit court and the court of appeals while benefitting from their analyses. Preisler v. Gen. Cas. Ins. Co., 2014 WI 135, ¶ 16, 360 Wis. 2d 129, 857 N.W.2d 136.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

State v. Carl Lee McAdory
2025 WI 30 (Wisconsin Supreme Court, 2025)
LCB, LLC v. Spectrum Brands, Inc.
Court of Appeals of Wisconsin, 2023
Riverback Farms, LLC v. Saukville Feed Supplies, Inc.
2023 WI App 40 (Court of Appeals of Wisconsin, 2023)
5 Walworth, LLC v. Engerman Contracting, Inc.
2023 WI 51 (Wisconsin Supreme Court, 2023)
Motorists Mut. Ins. Co. v. Ironics, Inc. (Slip Opinion)
2022 Ohio 841 (Ohio Supreme Court, 2022)
Daniel J. Hennessy, Jr. v. Wells Fargo Bank, N.A.
2022 WI 2 (Wisconsin Supreme Court, 2022)
5 Walworth, LLC v. Engerman Contracting, Inc.
2021 WI App 51 (Court of Appeals of Wisconsin, 2021)
Veritas Steel, LLC v. Lunda Construction Company
2020 WI 3 (Wisconsin Supreme Court, 2020)
Steadfast Ins. Co. v. Greenwich Ins. Co.
2019 WI 6 (Wisconsin Supreme Court, 2019)
Balde v. Haas
2019 WI App 1 (Court of Appeals of Wisconsin, 2018)
Archie A. Talley v. Mustafa Mustafa
2018 WI 47 (Wisconsin Supreme Court, 2018)
Fire Ins Exchange v. Oltmanns
2018 UT 10 (Utah Supreme Court, 2018)
Haley v. Kolbe & Kolbe Millwork Co.
866 F.3d 824 (Seventh Circuit, 2017)
Talley v. Mustafa
2017 WI App 31 (Court of Appeals of Wisconsin, 2017)
Drake-Williams Steel v. Continental Cas. Co.
883 N.W.2d 60 (Nebraska Supreme Court, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
2016 WI 14, 367 Wis. 2d 221, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wisconsin-pharmacal-company-llc-v-nebraska-cultures-of-california-inc-wis-2016.